Ivermectin as an inhibitor of cancer stem-like cells (2018)

Peer-Reviewed Study · Dominguez-Gomez G; Chavez-Blanco A; Medina-Franco JL; Saldivar-Gonzalez F; Flores-Torrontegui Y; et al. · February 2018

Dominguez-Gomez G et al., 2018-02: In vitro study reporting that ivermectin, identified by structural similarity to salinomycin, preferentially inhibits breast cancer stem-like cell populations and downregulates stemness genes.

The aim of the present study was to demonstrate that ivermectin preferentially inhibited cancer stem‑like cells (CSC) in breast cancer cells and downregulated the expression of 'stemness' genes.

n/a (PubMed abstract)

Dominguez-Gomez G et al., 2018-02: In vitro study reporting that ivermectin, identified by structural similarity to salinomycin, preferentially inhibits breast cancer stem-like cell populations and downregulates stemness genes. Study type: breast cancer cell lines with stem-cell-enriched mammosphere populations, in vitro. N: n/a. Country: Mexico (National Cancer Institute, Mexico City). Dose: not stated in the abstract. Funder/COI: not stated in the PubMed record. Comparator: parental (non-enriched) cells and salinomycin. This is the 'Dominguez-Gomez G et al., Mol Med Rep 2018' lead, confirmed. Also filed as IVA-11, IVA-17 (claims C3, C4, C6). Study type: lab.